Danaher to Acquire Masimo for $9.9 Billion
February 17, 2026
Danaher entered into a definitive agreement to acquire Masimo, paying $180 per share in cash for all outstanding shares. The deal values Masimo at approximately $9.9 billion (including assumed indebtedness and net of acquired cash) and is expected to close in the second half of 2026, subject to customary regulatory and shareholder approvals.
- Buyers
- Danaher Corporation
- Targets
- Masimo
- Industry
- Healthcare Services
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Masimo Acquires Sound United
April 12, 2022
Medical Devices
Masimo Corporation successfully completed its previously announced acquisition of Sound United. Sound United will operate as a division of Masimo under existing leadership from its headquarters in Carlsbad, California, bringing premium audio and home entertainment brands into Masimo’s portfolio.
-
Boston Scientific to Acquire Penumbra in $14.5 Billion Deal
January 16, 2026
Healthcare Services
Boston Scientific signed a definitive agreement to acquire Penumbra, Inc. for about $14.5 billion (enterprise value) in a cash-and-stock transaction. The deal is intended to expand Boston Scientific’s cardiovascular franchise and create a scaled position in mechanical thrombectomy and adjacent neurovascular markets, and is expected to close in 2026 subject to shareholder and regulatory approvals.
-
Haemonetics Corporation Acquires OpSens Inc.
December 12, 2023
Medical Devices
Haemonetics Corporation completed its acquisition of OpSens Inc. in an all-cash transaction for CAD $2.90 per share, representing a fully diluted equity value of approximately USD $255 million. The deal expands Haemonetics' hospital/interventional cardiology portfolio with OpSens' fiber-optic sensor technology (including the SavvyWire and OptoWire); OpSens will be delisted and Haemonetics expects OpSens to contribute $55–$65 million in revenue in fiscal 2025.
-
Novartis to Acquire MorphoSys in $2.9 Billion Deal
February 7, 2024
Pharmaceuticals
Novartis agreed to a voluntary public takeover offer to acquire MorphoSys AG for €68 per share, valuing the deal at about €2.7 billion (reported as $2.9 billion). The acquisition is intended to expand and complement Novartis’ oncology pipeline, including pelabresib (CPI-0610) and tulmimetostat (CPI-0209).
-
Siemens Acquires Dotmatics for $5.1 Billion
July 1, 2025
Cloud & SaaS
Siemens has completed its acquisition of Dotmatics, a Life Sciences R&D software provider, for an enterprise value of $5.1 billion. The deal expands Siemens’ AI-powered Siemens Xcelerator portfolio with Dotmatics’ Scientific Intelligence Platform (Luma) to create an end-to-end digital thread from research to production in life sciences.
-
Danaher Corporation Acquires Abcam plc
August 28, 2023
Biotechnology
Danaher Corporation agreed to acquire Abcam plc for $24.00 per share, representing an enterprise value of approximately $5.7 billion including assumed indebtedness. Abcam, headquartered in Cambridge, United Kingdom, will operate as a standalone company within Danaher's Life Sciences segment; the transaction is expected to close in mid-2024 and is subject to customary approvals.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.